Cytokine Inhibition in Patients With Chronic Fatigue Syndrome
Authors: Lily Chu
Journal: Annals of Internal Medicine (2017)

Letters19 September 2017Cytokine Inhibition in Patients With Chronic Fatigue SyndromeLily Chu, MD, MSHSLily Chu, MD, MSHSFrom Burlingame, California.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L17-0316 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:I commend Roerink and colleagues (1) for conducting a trial of an immunomodulator for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Few trials of pharmacotherapies for this condition are available despite its severity and high prevalence and the lack of any effective disease-modifying treatments.What was the prevalence of infectious and inflammatory symptoms in the study sample? Patients with ME/CFS often describe the profound exhaustion, muscle and joint aches, and other symptoms as being similar to those of influenza rather than the semantically identical but differently experienced symptoms that occur after, for example, a long hike. Although ...References1. Roerink ME, Bredie SJH, Heijnen M, Dinarello CA, Knoop H, Van der Meer JWM. Cytokine inhibition in patients with chronic fatigue syndrome. A randomized trial. Ann Intern Med. 2017;166:557-64. [PMID: 28265678]. doi:10.7326/M16-2391 LinkGoogle Scholar2. Green CR, Cowan P, Elk R, O'Neil KM, Rasmussen AL. National Institutes of Health Pathways to Prevention workshop: advancing the research on myalgic encephalomyelitis/chronic fatigue syndrome. Ann Intern Med. 2015;162:860-5. [PMID: 26075757]. doi:10.7326/M15-0338 LinkGoogle Scholar3. Roerink ME, van der Schaaf ME, Dinarello CA, Knoop H, van der Meer JW. Interleukin-1 as a mediator of fatigue in disease: a narrative review. J Neuroinflammation. 2017;14:16. [PMID: 28109186] doi:10.1186/s12974-017-0796-7 CrossrefMedlineGoogle Scholar4. Vallings R. A report from the 5th International AACFS Conference. Phoenix Rising. 6 March 2011. Accessed at http://phoenixrising.me/conferences-2/a-report-from-the-fifth-international-aacfs-conference-by-dr-rosamund-vallings on 1 April 2017. Google Scholar5. Tumor necrosis factor-alpha inhibition in chronic fatigue syndrome. ClinicalTrials.gov: NCT01730495. Accessed at https://clinicaltrials.gov/ct2/show/NCT01730495 on 1 April 2017. Google Scholar Author, Article, and Disclosure InformationAffiliations: From Burlingame, California.Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L17-0316. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCytokine Inhibition in Patients With Chronic Fatigue Syndrome Megan E. Roerink , Sebastian J.H. Bredie , Michael Heijnen , Charles A. Dinarello , Hans Knoop , and Jos W.M. Van der Meer Cytokine Inhibition in Patients With Chronic Fatigue Syndrome Megan E. Roerink and Jos W.M. Van der Meer Metrics 19 September 2017Volume 167, Issue 6Page: 447-448KeywordsChronic fatigue syndromeCytokinesDisclosureFatigueLymph nodesMusclesMyalgiaNecrosisPainPharyngitis ePublished: 19 September 2017 Issue Published: 19 September 2017 Copyright & PermissionsCopyright © 2017 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...